About SpringWorks Therapeutics: SpringWorks Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany, is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors. We developed and are commercializing the first and only FDA and EC approved medicine for adults with desmoid tumors and the first and only FDA and EC approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN). At SpringWorks, we are committed to finding answers people with rare tumors need.

We thrive in an atmosphere of passion and tenacity, fueled by the excitement of the possibilities science may unlock and driven to work with urgency because of the importance of our work. We value authenticity because diverse backgrounds, cultures, styles and abilities can only help us find the answers that people with rare tumors are looking for . S.

Market Access team, responsible for shaping the strategic direction and leading the development and execution of market access and pricing strategies to support the commercial success of pimicotinib for TGCT. This individual will lead the development of access strategies and tactics that communicate the differentiated value of pimicotinib to key external stakeholders—including payers, C-suite executives, provider networks, GPOs, pharmacists, and population-based decision-makers in community oncology. The Director will be accountable for delivering a suite of payer and provider-facing tools, field team resources, and non-personal engagement tactics to ensure optimal access and uptake.

Responsibilities

Requirements

: Education: Bachelor's degree (business or related disciplines) MBA or other advanced degree preferred Skills/Experience: 9+ years of pharmaceutical and/or biotech experienc

Director, Value, Access & Pricing- US Rare Tumors (TGCT)